Announcement of Availability for Acalabrutinib

February 07, 2024

The Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using acalabrutinib, an oral, next-generation inhibitor of Bruton’s tyrosine kinase (BTK) for nonHodgkin lymphomas (NHL), which is being developed by CTEP as an anticancer agent in collaboration with AstraZeneca. CTEP will also consider requests to supply acalabrutinib for nonclinical studies. All clinical and nonclinical researchers possessing an interest in working with the agent are welcome to apply. Proposals for clinical trials should be supported by a strong rationale and robust preclinical data (see “Components of a Competitive Letter of Intent” at http://ctep.cancer.gov/protocolDevelopment/lois_concepts.htm). All proposals approved by CTEP will be sent to the industry collaborator for a commitment to supply drug for the study.

If you are a DFHCC Investigator interested in submitting an LOI using Acalabrutinib through the ETCTN, please contact Dr. Geoffrey Shapiro (geoffrey_shapiro@dfci.harvard.edu)

Questions may be addressed to Dr. Percy Ivy (ivyp@ctep.nci.nih.gov), Associate Branch Chief, Investigational Drug Branch, CTEP, please CC Dr. Geoffrey Shapiro (geoffrey_shapiro@dfci.harvard.edu)